Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN program priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA center requests comments on fiscal 2003 program goals in June 21 Federal Register notice. Comments on ongoing broad program objective, new initiatives sought. Center asks which "B" list priorities from fiscal 2002 list should move to "A" status. Industry guidances on supplement regulation/labeling, "Food Security Action Plan," long-awaited supplements GMP reg were among "A" list priorities this year (1"The Tan Sheet" Feb. 4, 2002, p. 14). Ephedra strategy, transmissible spongiform encephalopathies goals were among "B" items. FDA seeks comments by Aug. 20...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel